Evidence map›Paper›PMID 40063946›Full record

ArticleJournal of medical Internet research2025

Assessment of the Efficiency of a ChatGPT-Based Tool, MyGenAssist, in an Industry Pharmacovigilance Department for Case Documentation: Cross-Over Study.

Alexandre Benaïche, Ingrid Billaut-Laden, Herivelo Randriamihaja, Jean-Philippe Bertocchio

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alexandre BenaïcheBayer Healthcare SAS France, Lille, France.ORCID 0009-0008-4407-2782
Ingrid Billaut-LadenBayer Healthcare SAS France, Lille, France.ORCID 0009-0007-8651-000X
Herivelo RandriamihajaBayer Healthcare SAS France, Lille, France.ORCID 0009-0005-5468-043X
Jean-Philippe BertocchioSKEZI, Les Papèteries-Image Factory, Annecy, France.ORCID 0000-0002-4104-702X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt the end of 2023, Bayer AG launched its own internal large language model (LLM), MyGenAssist, based on ChatGPT technology to overcome data privacy concerns. It may offer the possibility to decrease their harshness and save time spent on repetitive and recurrent tasks that could then be dedicated to activities with higher added value. Although there is a current worldwide reflection on whether artificial intelligence should be integrated into pharmacovigilance, medical literature does not provide enough data concerning LLMs and their daily applications in such a setting. Here, we studied how this tool could improve the case documentation process, which is a duty for authorization holders as per European and French good vigilance practices.

objectiveThe aim of the study is to test whether the use of an LLM could improve the pharmacovigilance documentation process.

methodsMyGenAssist was trained to draft templates for case documentation letters meant to be sent to the reporters. Information provided within the template changes depending on the case: such data come from a table sent to the LLM. We then measured the time spent on each case for a period of 4 months (2 months before using the tool and 2 months after its implementation). A multiple linear regression model was created with the time spent on each case as the explained variable, and all parameters that could influence this time were included as explanatory variables (use of MyGenAssist, type of recipient, number of questions, and user). To test if the use of this tool impacts the process, we compared the recipients' response rates with and without the use of MyGenAssist.

resultsAn average of 23.3% (95% CI 13.8%-32.8%) of time saving was made thanks to MyGenAssist (P<.001; adjusted R

conclusionsOur study is the first to show that a ChatGPT-based tool can improve the efficiency of a good practice activity without needing a long training session for the affected workforce. These first encouraging results could be an incentive for the implementation of LLMs in other processes.

Indexed as

DocumentationPharmacovigilanceAdverse Drug Reaction Reporting SystemsArtificial IntelligenceCross-Over StudiesDrug IndustryGenerative Artificial IntelligenceHumansartificial intelligenceChatGPTefficiencylarge language modelMyGenAssistpharmacovigilance

Identifiers

PMID40063946
PMCPMC11933758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.